Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Authors: Farid Cherbal, Lydia Ait Braham, Selma Lerari, Kada Boualga
Journal: Cancer Research (2020)

Abstract Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeria. We studied for the first time the clinicopathological and genetic features of prostate cancer in Algerian patients. Το date. inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes. Patients with hereditary prostate cancer have been screened for germline mutations in BRCA1, BRCA2, MLH1, MSH2 and PMS2 genes. Patients and Methods: The study population included 769 patients with prostate cancer from 31 provinces of Algeria (among 48) covered by the cancer registry of the anti-cancer center of Blida, Algeria. Patients referred with a biopsy proven diagnosis of carcinoma of the prostate to the anti cancer center of Blida, from January 2013 to April 2019 were studied. Clinical and tumor data: age at diagnosis, PSA value, Gleason score (New grading system groupe 1), TNM stage and family history of prostate cancer have been collected from the medical records of the patients. Five patients and one asymptomatic patient with strong hereditary prostate cancer history have been tested by PCR-direct sequencing for recurrent germline mutations already detected in Algerian patients with family history of breast cancer and prostate cancer or lynch syndrome, respectively. We analysed BRCA1 (exon 3 and 10), BRCA2 (exons 10, 16 and 19), MLH1 (exon 1), MSH2 (exon 5). In addition, for the first time, we screened exons 6 and 10 of PMS2 gene in prostate cancer patients. Results: The median age at diagnosis of prostate cancer was 70.73 years. 41.71 % patients have been diagnosed with prostate cancer under the age of 70 years. Majority of patients (95.39%) presented with a PSA value &amp;gt;4ng/ml. Of the tumors, 36.87% were Gleason score 3+3 (grade 1) and 26.36% were Gleason score 3+4 (grade 2) while Gleason score 4+3 (grade 3), 4+4 (grade 4) and 4+5 (grade 5) disease comprised 16.32%, 11.97 and 8.42% of cases, respectively. Our results showed that 87.5% of prostate cancer were diagnosed at TNM stage I (7.63%), TNM stage II (44.87%), TNM stage III (31.05%), TNM stage IV(3.95%), respectively. 85 patients (11.18%) had a family history of prostate cancer. The BRCA1 recurrent germline mutation c.2125_2126insA has been identified in asymptomatic patient aged of 61 years with a strong family history of prostate cancer and breast cancer. His father and two brothers died of prostate cancer. We detected the intronic variant of uncertain significance (UV) c.989-107_989-106insA in the exon 10 of PMS2 gene in a suspected Lynch syndrome patient diagnosed with colon cancer at age 65 years and a prostate cancer at age 77 years, respectively. Interestingly, one son of this patient has developed colon cancer at age 34 years. BRCA2, MLH1 and MSH2 recurrent germline mutations have not been detected in our prostate cancer patients. Conclusions: The accumulative knowledge about clinicopathological features in prostate cancer patients will have an effect on clinical management in the areas of both prevention and treatment. Genetic testing of hereditary prostate cancer will have an important management implications for Algerian patients and their families. Citation Format: Farid Cherbal, Lydia Ait Braham, Selma Lerari, Kada Boualga. Clinicopathological and genetic features of prostate cancer in Algerian patients: First report [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 4602.